News
MRSN
--
0.00%
--
BRIEF-Mersana Therapeutics Announces 2022 Strategic Priorities And Milestones
reuters.com · 01/07 14:48
Mersana Therapeutics outlines upcoming milestones for 2022
Ahead of a business update scheduled at the J.P. Morgan Healthcare Conference next week, Mersana Therapeutics (NASDAQ:MRSN) shared the anticipated timeline for 2022 milestones in the company’s ongoing clinical programs.
Seekingalpha · 01/07 13:25
Mersana Therapeutics Outlines 2022 Strategic Priorities, Milestones
UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022 UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in platinum-sensitive ovarian
Benzinga · 01/07 13:02
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer
Sutro stock collapsed Thursday — and was among the biggest biotech stock dives — after its ovarian cancer study disappointed investors.
Investor's Business Daily · 01/06 18:13
Strong Insider Buying Could Indicate a Bottom in These 3 Stocks
Every investor knows that the path toward profits lies in buying low and selling high. That’s a basic precept of any economic trading system. The trick, however, is recognizing when the stock is low enough to buy in. The prime moment to buy is when the sto...
TipRanks · 01/06 01:57
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 01/05 13:20
Mersana Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...
GlobeNewswire · 01/05 13:00
Mersana says Bain Capital raised passive stake to over 7%
Mersana Therapeutics (MRSN +2.6%) is trading higher in morning hours after announcing that Bain Capital has raised its stake its stake in the company to ~7.3%. On Dec. 29 and
Seekingalpha · 01/04 15:25
Mersana Therapeutics Named to 2021 List of Top Places to Work in Massachusetts by The Boston Globe
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...
GlobeNewswire · 12/02/2021 13:00
Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B
Synaffix B.V. has expanded its license agreement with Mersana Th
Benzinga · 11/30/2021 12:55
Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high ...
GlobeNewswire · 11/23/2021 13:00
BRIEF-Mersana Therapeutics And Synaffix B.V. Enter Into An Amended, Restated Commercial License And Option Agreement
reuters.com · 11/23/2021 12:41
Mersana Therapeutics's Return On Capital Employed Insights
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 11.17%, resulting in a loss of $45.39 million.
Benzinga · 11/10/2021 16:51
Mersana Therapeutics to Present at the Upcoming Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high ...
GlobeNewswire · 11/10/2021 13:00
--Baird Adjusts Price Target on Mersana Therapeutics to $23 From $30, Keeps Outperform Rating
MT Newswires · 11/10/2021 12:46
--Wedbush Trims Price Target for Mersana Therapeutics to $23 From $25, Maintains Outperform Rating
MT Newswires · 11/09/2021 14:52
BRIEF-Mersana Therapeutics Files For Mixed Shelf Of Up To $300 Million
reuters.com · 11/09/2021 14:33
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
Zacks.com · 11/09/2021 12:15
Mersana Therapeutics Q3 EPS $(0.63) Misses $(0.58) Estimate
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent. This is a 90.91 percent decrease over losses of $(0.33) per share
Benzinga · 11/09/2021 11:03
Mersana Therapeutics EPS misses by $0.05, beats on revenue
Mersana Therapeutics (NASDAQ:MRSN): Q3 GAAP EPS of -$0.63 misses by $0.05. Cash and cash equivalents as of September 30, 2021 of $191.7M Press Release
Seekingalpha · 11/09/2021 11:03
Webull provides a variety of real-time MRSN stock news. You can receive the latest news about Mersana through multiple platforms. This information may help you make smarter investment decisions.
About MRSN
Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.